Literature DB >> 25536410

Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012.

Qiuping Gu, Ryne Paulose-Ram, Vicki L Burt, Brian K Kit.   

Abstract

During 2003–2012, there was a significant increase in the percentage of adults aged 40 and over who used a prescription cholesterol-lowering medication. In 2003–2004, one in five adults reported using a prescription cholesterol-lowering medication in the past 30 days. By 2011–2012, that number had risen to one in four adults. In 2011–2012, the majority of adults using a cholesterol-lowering medication reported using a statin alone (83%). Ten percent used both a statin and a nonstatin and another 7% used only a nonstatin. Simvastatin was the most commonly used medication, with 42% of all cholesterol-lowering medication users reporting its use, followed by atorvastatin (20.2%). Use of a prescription cholesterol-lowering medication increased with age but was similar between men and women and race and Hispanic origin groups. Adults aged 40–64 who reported having health insurance or prescription medication coverage were more likely to take prescription cholesterol-lowering medications. Hypercholesterolemia or high cholesterol is one of the most common preventable risk factors for atherosclerotic CVD. In 2011–2012, more than 30 million Americans aged 20 and over (13%) had measured high total cholesterol (5). There is extensive and consistent evidence supporting the use of cholesterol-lowering medication, especially statins, in addition to lifestyle changes, to treat lipid disorders and reduce atherosclerotic CVD events. The 2013 cholesterol treatment guidelines updated recommendations for statin therapy on the basis of low-density lipid cholesterol levels and atherosclerotic CVD risks (6). Approximately 71% of adults with diagnosed CVD, 63% of those with diagnosed diabetes, and 54% of those with diagnosed hypercholesterolemia reported taking prescription cholesterol-lowering medications. All material appearing in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25536410

Source DB:  PubMed          Journal:  NCHS Data Brief        ISSN: 1941-4935


  88 in total

1.  Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users.

Authors:  Zachary A Marcum; Hsiao-Ching Huang; Robert J Romanelli
Journal:  J Gen Intern Med       Date:  2019-07-31       Impact factor: 5.128

Review 2.  Consensus statement on the management of dyslipidemia in Indian subjects: A different perspective.

Authors:  Enas A Enas; T S Dharmarajan; Basil Varkey
Journal:  Indian Heart J       Date:  2015-04-30

3.  Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?

Authors:  Daniel S Streetman; Stephen M Stout
Journal:  CMAJ       Date:  2015-02-02       Impact factor: 8.262

Review 4.  A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.

Authors:  Khoa A Nguyen; Lang Li; Deshun Lu; Aida Yazdanparast; Lei Wang; Rolf P Kreutz; Elizabeth C Whipple; Titus K Schleyer
Journal:  Eur J Clin Pharmacol       Date:  2018-05-22       Impact factor: 2.953

5.  The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.

Authors:  Corey J Lum; Kazuma Nakagawa; Ralph V Shohet; Todd B Seto; Deborah A Taira
Journal:  Hawaii J Med Public Health       Date:  2017-04

Review 6.  Chemoprevention of Colorectal Cancer.

Authors:  Bryson W Katona; Jennifer M Weiss
Journal:  Gastroenterology       Date:  2019-09-26       Impact factor: 22.682

7.  Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry.

Authors:  Ann Marie Navar; Tracy Y Wang; Shuang Li; Jennifer G Robinson; Anne C Goldberg; Salim Virani; Veronique L Roger; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Eric D Peterson
Journal:  Am Heart J       Date:  2017-08-12       Impact factor: 4.749

8.  Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining.

Authors:  Camille Morival; Richard Westerlynck; Guillaume Bouzillé; Marc Cuggia; Pascal Le Corre
Journal:  Eur J Clin Pharmacol       Date:  2017-12-18       Impact factor: 2.953

9.  Markers of cholesterol synthesis are elevated in adolescents and young adults with type 2 diabetes.

Authors:  Ivana Semova; Amy E Levenson; Joanna Krawczyk; Kevin Bullock; Kathryn A Williams; R Paul Wadwa; Philip R Khoury; Thomas R Kimball; Elaine M Urbina; Sarah D de Ferranti; David M Maahs; Lawrence M Dolan; Amy S Shah; Clary B Clish; Sudha B Biddinger
Journal:  Pediatr Diabetes       Date:  2020-09-15       Impact factor: 4.866

10.  Safety and Efficacy of Atorvastatin for Chronic Subdural Hematoma in Chinese Patients: A Randomized ClinicalTrial.

Authors:  Rongcai Jiang; Shiguang Zhao; Renzhi Wang; Hua Feng; Jianmin Zhang; Xingang Li; Ying Mao; Xianrui Yuan; Zhou Fei; Yuanli Zhao; Xinguang Yu; Wai Sang Poon; Xide Zhu; Ning Liu; Dezhi Kang; Tao Sun; Baohua Jiao; Xianzhi Liu; Rutong Yu; Junyi Zhang; Guodong Gao; Jiehe Hao; Ning Su; Gangfeng Yin; Xingen Zhu; Yicheng Lu; Junji Wei; Jin Hu; Rong Hu; Jianrong Li; Dong Wang; Huijie Wei; Ye Tian; Ping Lei; Jing-Fei Dong; Jianning Zhang
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.